Wilson Therapeutics (No_rec, TP: SEK) - Discontinuing coverage
We have discontinued coverage of Wilson Therapeutics. Our last published recommendation, target price and estimates should no longer be relied upon.Wilson Therapeutics AB is a Sweden-based biopharmaceutical company that is active in the development of a treatment for Wilson disease. Wilson disease is a genetic disease that causes copper poisoning. The Company's main product is Decuprate (tetrathiomolybdate), a de-coppering agent with a mechanism of action enabling it to bind copper to restore, in part or in whole, the body's own buffer system for copper in the liver. Decuprate also restores the natural excretion route via the bile rather than preventing copper to be absorbed or excreted through the kidneys. The Company operates through the Swedish subsidiaries Wilson Therapeutics Incentive AB and TTM Europe Development AB, as well as through Wilson Therapeutics Inc, a subsidiary based in the United States.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.